MedTrace Logo

Risk of Hepatocellular Carcinoma in Patients Treated With ETV vs TDF for Chronic Hepatitis B With Compensated Cirrhosis

NCT04160897 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 4000

Last updated 2019-11-13

No results posted yet for this study

Summary

The current first-line treatment for HBV is long-term oral antiviral drugs to inhibit HBV DNA replication. First-line antiviral drugs recommended by the Chinese 2015 Hepatitis B Guidelines include ETV and TDF. This study is based on a real-world clinical cohort to retrospectively analyze the effects of ETV and TDF on the long-term (5-year) incidence of HCC in Chinese patients with chronic hepatitis B with compensated cirrhosis. The results will guide the revision of the Chinese HBV guidelines.

Conditions

Interventions

DRUG

Entecavir

entecavir naive for chronic hepatitis B patients

DRUG

Tenofovir Disoproxil

tenofovir disopropyl naive for chronic hepatitis B patients

Sponsors & Collaborators

  • Shanghai MedSci Healthcare Co. Ltd

    collaborator UNKNOWN

  • Qing XIe

    lead OTHER

Principal Investigators

  • Qing Xie, MD · Director of Department of Infectious Disease, Rui Jin Hospital

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-22
Primary Completion
2020-10-31
Completion
2020-10-31
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04160897 on ClinicalTrials.gov